Assembly Biosciences (NASDAQ:ASMB) Stock Price Down 6.3% – Time to Sell?

Assembly Biosciences, Inc. (NASDAQ:ASMB) dropped 6.3% during mid-day trading on Thursday . The company traded as low as $31.02 and last traded at $30.80. 80,476 shares were traded during mid-day trading, a decline of 52% from the average daily volume of 167,561 shares. The stock had previously closed at $32.87.

More Assembly Biosciences News

Here are the key news stories impacting Assembly Biosciences this week:

• Positive Sentiment: HC Wainwright raised multiple earnings forecasts and maintained its Buy rating. The firm increased its FY2027 estimate from a loss of $0.02 per share to earnings of $0.05, raised its Q2 and Q3 2027 estimates to losses of $0.83 and $0.84 per share, respectively, and lifted its Q4 2027 forecast to $1.67 per share. It also raised its FY2028 estimate to $0.84, FY2030 estimate to $3.32, and FY2029 forecast to a loss of $2.22 per share. HC Wainwright retained a $50 price target, implying substantial upside from recent trading levels.
• Positive Sentiment: The revisions suggest HC Wainwright sees improving future profitability for Assembly Biosciences, particularly beginning in 2027 and extending into 2028-2030. This could support investor confidence in the company’s pipeline and commercial prospects.
• Neutral Sentiment: Management will present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference on September 16 at 8:30 a.m. Eastern Time. The presentation could provide updates on Assembly’s viral- and liver-disease programs, but no new information was disclosed in the announcement. Assembly Biosciences conference presentation announcement
• Neutral Sentiment: The reported short-interest data showed zero shares short and a zero-day short-interest ratio, with no meaningful change from the prior period. Because the figures appear anomalous, they provide little insight into current trading pressure.

Analysts Set New Price Targets

A number of research analysts recently weighed in on ASMB shares. UBS Group assumed coverage on shares of Assembly Biosciences in a research note on Tuesday, September 1st. They set a “buy” rating and a $52.00 target price on the stock. Mizuho set a $53.00 price objective on Assembly Biosciences in a research report on Tuesday, September 1st. Wall Street Zen lowered Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. Zacks Research upgraded Assembly Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 20th. Finally, Guggenheim restated a “buy” rating and issued a $43.00 price target on shares of Assembly Biosciences in a research note on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.60.

Assembly Biosciences Trading Down 2.2%

The firm’s 50 day simple moving average is $29.77 and its 200 day simple moving average is $28.39. The firm has a market cap of $606.73 million, a PE ratio of 29.22 and a beta of 1.13.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.52. The firm had revenue of $13.37 million during the quarter, compared to analyst estimates of $8.60 million. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%. As a group, equities research analysts predict that Assembly Biosciences, Inc. will post 2.28 earnings per share for the current fiscal year.

Institutional Trading of Assembly Biosciences

Large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its position in shares of Assembly Biosciences by 6,382.7% during the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 3,319 shares during the last quarter. California State Teachers Retirement System purchased a new stake in Assembly Biosciences during the second quarter valued at $103,000. Seven Fleet Capital Management LP bought a new position in Assembly Biosciences during the fourth quarter valued at $147,000. Acadian Asset Management LLC lifted its position in Assembly Biosciences by 42.1% during the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 6,823 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. purchased a new position in shares of Assembly Biosciences in the 4th quarter worth $228,000. Institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.